Access to essential anticancer medicines for children and adolescents

Cancer medicines on the WHO model list of essential medicines: processes, challenges, and a way forward

ESMO 2022: Lung roundup

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Defining value based care for LMICs

Building collaborations for cancer research

Defining Value in Indian healthcare: Asking the right questions

ESMO 2022: Breast and ovarian trial analysis

ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer